STIM vs. MDXG, INMD, BBNX, KMTS, IRMD, SIBN, CBLL, EMBC, AVNS, and RXST
Should you be buying Neuronetics stock or one of its competitors? The main competitors of Neuronetics include MiMedx Group (MDXG), InMode (INMD), Beta Bionics (BBNX), Kestra Medical Technologies (KMTS), iRadimed (IRMD), SiBone (SIBN), CeriBell (CBLL), Embecta (EMBC), AVANOS MEDICAL (AVNS), and RxSight (RXST). These companies are all part of the "medical equipment" industry.
Neuronetics vs. Its Competitors
Neuronetics (NASDAQ:STIM) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.
Neuronetics has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500.
MiMedx Group has a net margin of 11.40% compared to Neuronetics' net margin of -53.67%. MiMedx Group's return on equity of 22.70% beat Neuronetics' return on equity.
MiMedx Group has higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
In the previous week, MiMedx Group had 4 more articles in the media than Neuronetics. MarketBeat recorded 5 mentions for MiMedx Group and 1 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.87 beat MiMedx Group's score of 0.68 indicating that Neuronetics is being referred to more favorably in the media.
53.6% of Neuronetics shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 9.8% of Neuronetics shares are held by company insiders. Comparatively, 1.7% of MiMedx Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Neuronetics currently has a consensus target price of $5.50, suggesting a potential upside of 55.81%. MiMedx Group has a consensus target price of $12.50, suggesting a potential upside of 110.44%. Given MiMedx Group's stronger consensus rating and higher probable upside, analysts plainly believe MiMedx Group is more favorable than Neuronetics.
Summary
MiMedx Group beats Neuronetics on 11 of the 15 factors compared between the two stocks.
Get Neuronetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding STIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neuronetics Competitors List
Related Companies and Tools
This page (NASDAQ:STIM) was last updated on 6/29/2025 by MarketBeat.com Staff
Free STIM Stock Alerts